Esperion Therap (ESPR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov25

Piper Sandler Upgrades Esperion Therapeutics to Overweight with $9 Price Target

11:50

Nov21

Esperion Therapeutics and Otsuka launch NEXLETOL® in Japan

13:20

Nov18

Esperion Therapeutics partner HLS Therapeutics announces NILEMDO® approval in Canada

12:26

Nov12

US Bank Maintains Esperion Sell Rating and Raises Target Price

12:47

Nov10

Esperion Reports New Data on NEXLETOL Cardiovascular Efficacy at Scientific Meeting

13:01

Nov6

Esperion Therapeutics released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 87.31 M (forecast USD 77.2 M), actual EPS USD -0.156 (forecast USD -0.0782)

14:30

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 87.31 M, Net Income -31.33 M, EPS -0.156

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 82.39 M, Net Income -12.73 M, EPS -0.0644

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 65 M, Net Income -40.46 M, EPS -0.2099

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change